Notification of Communications with FDA. Within 30 days after the date of any written report, correspondence, or communication between GSK and the FDA that materially discusses GSK’s or a Covered Person’s actual or potential unlawful or improper promotion of GSK’s products (including any improper dissemination of information about off-label indications), GSK shall provide a copy of the report, correspondence, or communication to the OIG. GSK shall also provide written notice to the OIG within 30 days after the resolution of any such disclosed off-label matter, and GlaxoSmithKline LLC Corporate Integrity Agreement shall provide the OIG with a description of the findings and/or results of the matter, if any.
Appears in 4 contracts
Samples: Corporate Integrity Agreement, Corporate Integrity Agreement, Corporate Integrity Agreement